ImmunoPrecise Antibodies Ltd's (CVE:IPA) president and chief executive Jennifer Bath caught up with Proactive Investors at the Spring Investor Summit 2019 in New York City.
Operating from their laboratory facilities at the Vancouver Island Technology Park in Victoria, British Columbia … ImmunoPrecise is an 'end-to-end' provider for accelerated antibody research and discovery.
Price: 2.44 CAD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...
FOR OUR FULL DISCLAIMER CLICK HERE
Director Interviews
ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...
Industry & services
Retail & consumer
Prev article
